Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 20 de 1.172
1.
Wien Med Wochenschr ; 171(5-6): 94-101, 2021 Apr.
Article En | MEDLINE | ID: mdl-33689085

Skeletal disorders are inherited disorders with significant skeletal involvement and most of them are rare or extremely rare. Based on the clinical, radiological and genetic phenotype, the group of skeletal disorder comprises more than 450 different and highly heterogeneous disorders. In skeletal disorders rapid and precise diagnoses are urgently needed for patient care and are based on the combination of clinical, radiological and genetic analysis. Novel genetic techniques have revolutionized diagnostics and have a huge impact on counseling of patients and families. Disease-specific long-term management in a multidisciplinary healthcare team in highly specialized centers is recommended to optimize care for these patients. Here we describe a multidisciplinary postnatal approach for the diagnosis and management of patients and families with rare skeletal disorders at the Vienna Bone and Growth Center. We discuss the value of a multidisciplinary diagnostic and management approach in the postnatal setting and provide a diagnostic flowchart for rare skeletal disorders.


Genetic Testing , Rare Diseases , Humans , Phenotype , Rare Diseases/diagnosis , Rare Diseases/therapy
2.
Value Health ; 24(3): 431-442, 2021 03.
Article En | MEDLINE | ID: mdl-33641778

OBJECTIVES: To analyze whether the adoption of a societal perspective would alter the results and conclusions of economic evaluations for rare disease-related healthcare technologies. METHODS: A search strategy involving all the active substances considered as orphan drugs by the European Medicines Agency plus a list of 76 rare diseases combined with economic-related terms was conducted on Medline and the Cost-Effectiveness Registry from the beginning of 2000 until November 2018. We included studies that considered quality-adjusted life years as an outcome, were published in a scientific journal, were written in English, included informal care costs or productivity losses, and separated the results according to the applied perspective. RESULTS: We found 14 articles that fulfilled the inclusion criteria. Productivity losses were considered in 12 studies, the human capital approach being the method most frequently used. Exclusively, informal care was considered in 2 articles, being valued through the opportunity cost method. The 14 articles selected resulted in 26 economic evaluation estimations, from which incremental cost-utility ratio values changed from cost-effective to dominant in 3 estimates, but the consideration of societal costs only modified the authors' conclusion in 1 study. CONCLUSIONS: The presence of societal costs in the economic evaluation of rare diseases did not affect the conclusions of the studies except in a single specific case. In those studies where the societal perspective was considered, we did not find significant changes in the economic evaluation results due to the higher costs of treatments and the low quality-adjusted life-years gained.


Cost of Illness , Cost-Benefit Analysis/methods , Rare Diseases/economics , Rare Diseases/therapy , Efficiency , Europe , Humans , Models, Economic , Quality-Adjusted Life Years
5.
Int J Mol Sci ; 22(2)2021 Jan 12.
Article En | MEDLINE | ID: mdl-33445477

There is no single global definition of a rare disease, and for different geographical areas the definition is based on the disease occurrence in that population [...].


Biomarkers , Rare Diseases/diagnosis , Rare Diseases/etiology , Rare Diseases/therapy , Disease Management , Disease Susceptibility , Humans
6.
Cancer Radiother ; 25(2): 169-174, 2021 Apr.
Article En | MEDLINE | ID: mdl-33436284

Intramedullary spinal cord metastases (ISCM) is a rare, but devastating complication of malignant disease. Prognosis is poor, with an overall median survival (OS) of 4 months from the time of diagnosis. Yet, ISCMs are being increasingly diagnosed, related to advances and increased use of imaging and therapies that prolong survival in patients with cancer. Prompt and accurate diagnosis of ISCM is necessary for effective treatment, and magnetic resonance imaging (MRI) is the preferred imaging technique. The optimal management of these patients is controversial because of the multitude of clinical circumstances and the lack of controlled studies on the efficacy of the different therapeutic approaches. Increased awareness of this rare entity may lead to an earlier diagnosis at a stage when neurological deficits are reversible, and therefore, more effective palliation may be achieved. Therefore, we carried out this retrospective research of 3 observations of ISCM, associated with a detailed review of the literature describing the diagnostic, therapeutic and evolutionary characteristics of this special rare entity.


Adenocarcinoma/secondary , Carcinosarcoma/secondary , Rare Diseases/etiology , Spinal Cord Neoplasms/secondary , Adenocarcinoma/complications , Adenocarcinoma/diagnostic imaging , Adenocarcinoma/therapy , Adult , Breast Neoplasms/pathology , Carcinosarcoma/complications , Carcinosarcoma/diagnostic imaging , Carcinosarcoma/therapy , Early Detection of Cancer , Fatal Outcome , Female , Humans , Lumbar Vertebrae , Lung Neoplasms/pathology , Magnetic Resonance Imaging , Male , Middle Aged , Rare Diseases/diagnostic imaging , Rare Diseases/therapy , Retrospective Studies , Spinal Cord Neoplasms/complications , Spinal Cord Neoplasms/diagnostic imaging , Spinal Cord Neoplasms/therapy , Thoracic Vertebrae
7.
Cad Saude Publica ; 36(12): e00115720, 2020.
Article Pt | MEDLINE | ID: mdl-33331552

The article proposes to discuss the many complexities involved in the incorporation of new health technologies for rare diseases, with a central focus on the case of cystic fibrosis. Cystic fibrosis was chosen because it is a autosomal recessive genetic disorder, considered the most common of the rare diseases. The disease has also benefited greatly from investments in research in the field of molecular biology, mainly in the United States, but also among European research groups, which resulted in the registration and marketing of four new drugs. These new drugs act for the first time on the basic defect in cystic fibrosis. From a perspective that views rare diseases as a field of research woven among many others, the article aims to problematize cystic fibrosis from a more person-centered approach, the duality of witnessing from afar the molecularization of life, the emergence of last-generation drugs that interrupt, at the molecular level, the cascade of errors and thus the symptoms and evolution of the disease. The article aims to bring various elements to the debate that traverse the complex local reality of Brazilian cystic fibrosis patients in a global context of technological innovation and with a break in the treatment paradigm. Based on the field of rare diseases, including the presentation of cystic fibrosis in the age of precision medicine, alongside discussions on biopolitics in a context of health innovation and high-cost drugs, the article aims to shed light on the current challenges and possibilities.


Cystic Fibrosis , Brazil , Cystic Fibrosis/therapy , Cystic Fibrosis Transmembrane Conductance Regulator , Humans , Precision Medicine , Rare Diseases/therapy
9.
Orphanet J Rare Dis ; 15(1): 228, 2020 08 31.
Article En | MEDLINE | ID: mdl-32867855

During the COVID-19 outbreak, the European Reference Network on Rare Bone Diseases (ERN BOND) coordination team and Italian rare bone diseases healthcare professionals created the "COVID-19 Helpline for Rare Bone Diseases" in an attempt to provide high-quality information and expertise on rare bone diseases remotely to patients and healthcare professionals. The present position statement describes the key characteristics of the Helpline initiative, along with the main aspects and topics that recurrently emerged as central for rare bone diseases patients and professionals. The main topics highlighted are general recommendations, pulmonary complications, drug treatment, trauma, pregnancy, children and elderly people, and patient associations role. The successful experience of the "COVID-19 Helpline for Rare Bone Diseases" launched in Italy could serve as a primer of gold-standard remote care for rare bone diseases for the other European countries and globally. Furthermore, similar COVID-19 helplines could be considered and applied for other rare diseases in order to implement remote patients' care.


Betacoronavirus , Bone Diseases/complications , Coronavirus Infections/complications , Pneumonia, Viral/complications , Rare Diseases/complications , Remote Consultation/standards , Aged , Algorithms , Bone Diseases/therapy , Child , Coronavirus Infections/prevention & control , Coronavirus Infections/therapy , Female , Humans , Pandemics/prevention & control , Pneumonia, Viral/prevention & control , Pneumonia, Viral/therapy , Pregnancy , Rare Diseases/therapy , Wounds and Injuries
11.
J Bras Nefrol ; 42(2 suppl 1): 36-40, 2020 Aug 26.
Article En, Pt | MEDLINE | ID: mdl-32877497

During the Covid-19 pandemic, the issue is how to maintain adequate care for people with other diseases. In this document, the SBN Rare Diseases Committee (COMDORA) gives some guidelines on the care of patients with rare kidney diseases. These patients should follow the recommendations for the general population, bearing in mind that, as they have chronic kidney disease, they are included in the risk group for more serious outcomes if they develop Covid-19. Non-essential decision-making procedures should be postponed. In stable cases under appropriate treatment, we must choose to contact our patients remotely, using teleconsultations and home exam collections (if possible). In the presence of a symptom or sign of decompensation of the underlying disease, or infection with Sars-cov-2, advise the patient to seek medical assistance. The patient should not be waiting to get worse. Changes to the prescription should only be made on a scientific basis. Dosage suspension or change is not recommended, even in cases in which the patient needs to go to a center to receive his medication; in this case, the infusion center must follow the recommendations of the Ministry of Health. If the patient develops Covid-19 and uses any drugs, check the need for dose adjustment of the routine medications. Avoid the use of antimetabolics and anti-CD20 in patients with Covid-19, as they reduce viral clearance and predispose to bacterial infections. Contact between the patient and the medical team is essential; changes are recommended only with specialized medical guidance.


Betacoronavirus , Coronavirus Infections/epidemiology , Kidney Diseases/therapy , Pneumonia, Viral/epidemiology , Rare Diseases/therapy , Brazil , Coronavirus Infections/diagnosis , Coronavirus Infections/drug therapy , Drug Interactions , Humans , Pandemics , Patient Acceptance of Health Care , Pneumonia, Viral/diagnosis , Pneumonia, Viral/drug therapy , Symptom Assessment
12.
Rev. cuba. pediatr ; 92(3): e925, jul.-set. 2020. tab, graf
Article Es | LILACS, CUMED | ID: biblio-1126772

Introducción: La terapia física intensiva en enfermedades huérfanas, es un método para el tratamiento a pacientes con diferentes trastornos neurológicos, especialmente en la disfunción neuromuscular y musculo esquelética, como secuelas de las crisis metabólicas padecidas por una enfermedad neurodegenerativa que se caracteriza porque los afectados presentan un olor particular en la orina, semejante al jarabe de arce usado como alimento. Objetivo: Describir los resultados obtenidos a través de la aplicación de la terapia física intensiva en enfermedades huérfanas en un paciente. Presentación del caso: Niño de 9 años, con secuelas secundarias a la enfermedad neurodegenerativa citada. La evaluación inicial se realizó a través del índice de función motora GMFM 88-66, aplicado antes y después de cada intervención. El tratamiento consistió en el desarrollo del programa basado en la terapia física intensiva, en cuatro sesiones, durante cuatro semanas, cuatro horas por día, sin interrupción, con un total de 80 horas por cada intervención. Conclusiones: La terapia física intensiva en enfermedades huérfanas, proporciona cambios significativos en comparación con la fisioterapia tradicional. Combina varias técnicas fundamentadas en la base fisiológica del ejercicio, aumenta la posibilidad de mejoras en las secuelas a nivel motor en el caso de enfermedad neurodegenerativa y mejora la función motora gruesa en el niño. En general, se aprecian cambios en la evolución del paciente e impacto en el sistema musculo esquelético, disfunción neuromuscular y mejoría en su calidad de vida y clínica. Puede ser aplicable en otros niños con alteraciones motoras secundarias a enfermedades huérfanas o raras(AU)


Introduction: Intensive physical therapy in orphan diseases is a method for the treatment of patients with different neurological disorders, especially neuromuscular and skeletal muscle dysfunction as a consequence of metabolic crisis suffered due to a neurodegenerative disease which has as a characteristic that the patients present a particular smell in the urine, similar to the maple syrup used as food. Objective: To describe the results obtained through the use of intensive physical therapy in patients with orphan diseases. Case presentation: Nine years old boy with secondary sequelae of the above mentioned neurodegenerative disease. The initial evaluation was made with the index of motor function called GMFM 88-66 used before and after each intervention. The treatment involves the development of a program based in the intensive physical therapy in 4 sessions during 4 weeks and 4 hours each day, without stops and with a total of 80 hours per each intervention. Conclusions: Intensive physical therapy in orphan diseases provides significant changes in comparison with the traditional physiotherapy. It combines different techniques focused in the physiologic base of the exercises; in the case of neurodegenerative diseases, it increased the chances of improvement in the sequelaes of the motor level, and it improved the gross motor function in the boy. In general terms, there is evidence of changes in the evolution of the patient and impact in the skeletal muscle system, in the neuromuscular dysfunction and improvement in the clinical and life quality. This technique can be used in other children with motor disruptions secondary to orphan or rare diseases(AU)


Humans , Male , Child , Exercise , Physical Therapy Modalities/standards , Rare Diseases/therapy , Psychomotor Performance/physiology
13.
Article En | MEDLINE | ID: mdl-32824597

Background: Increasing attention is being paid to improve the quality of life of patients with rare diseases in China. However, we are currently unaware of the problems encountered in the medical services of rare diseases from the viewpoints of doctors and patients. This study addressed the differences in the perceived barriers of diagnosis and treatments for rare diseases between doctors and patients in China. Methods: Two independent cross-sectional surveys on the perception of Chinese doctors' and patients' experiences with rare diseases were launched online between January and February 2018. A non-probability, convenience sampling method was employed to recruit participants. Results: In all, 45 rare diseases were reported by 139 doctors and 1853 patients. Patients with rare diseases faced significantly more difficulties in receiving accurate diagnosis (72.0%) and accessing information related to diagnosis and treatment (77.3%) as compared with doctors (34.5% and 40.3%, p < 0.0001, respectively). Specially, patients felt more difficulties than doctors in obtaining sustainable treatment for rare diseases (84.3% vs. 49.6%, p < 0.001). A higher percentage of patients (58.7%) than that of doctors (39.1%) had concerns in terms of the affordability of drugs. Further, 66.3% patients claimed that the drugs used to treat their conditions were not covered by their current medical insurances, whereas only 21.6% for doctors (p < 0.0001). Moreover, 35.3% of doctors responded that they recommended patients to visit the specialist they knew or were acquainted with, whereas 30.0% of patients said that their doctors chose to treat them based on their past experiences (p < 0.001). Conclusion: The perceived experience of patients with regard to diagnosis and treatment was significantly different from that of doctors. An integrated medical service platform should be established to facilitate better communication and mutual understanding of rare diseases between patients and doctors.


Quality of Life , Rare Diseases , Adolescent , Adult , Aged , China , Cross-Sectional Studies , Female , Humans , Male , Middle Aged , Rare Diseases/diagnosis , Rare Diseases/therapy , Surveys and Questionnaires , Young Adult
14.
Ann Hematol ; 99(9): 1967-1977, 2020 Sep.
Article En | MEDLINE | ID: mdl-32621178

Thalassemia is characterized by a defect in the synthesis of one or more of the globin subunits of hemoglobin. This defect results in imbalance in the α/ß-globin chain ratio, ineffective erythropoiesis, chronic hemolytic anemia, and iron overload. With advances in diagnosis, treatment, and transfusion support, the prognosis of patients with thalassemia has improved over the past few decades. An increasing number of patients with thalassemia is living with long-term complications, including cardiomyopathy, chronic liver disease, endocrinopathy, and infections. In this paper, we review common complications that bring the patient with thalassemia to urgent or emergent medical attention. We also discuss the aspects of emergency care that are most relevant while caring for the patient with thalassemia in the emergency department.


Emergency Medical Services/trends , Emergency Service, Hospital/trends , Rare Diseases/diagnostic imaging , Rare Diseases/therapy , Thalassemia/diagnostic imaging , Thalassemia/therapy , Betacoronavirus , Blood Transfusion/methods , Blood Transfusion/trends , Cardiomyopathies/diagnostic imaging , Cardiomyopathies/epidemiology , Cardiomyopathies/therapy , Coronavirus Infections/diagnostic imaging , Coronavirus Infections/epidemiology , Coronavirus Infections/therapy , Diagnosis, Differential , Emergency Medical Services/methods , Humans , Liver Diseases/diagnostic imaging , Liver Diseases/epidemiology , Liver Diseases/therapy , Pandemics , Pneumonia, Viral/diagnostic imaging , Pneumonia, Viral/epidemiology , Pneumonia, Viral/therapy , Rare Diseases/epidemiology , Thalassemia/epidemiology
15.
Health Qual Life Outcomes ; 18(1): 177, 2020 Jun 10.
Article En | MEDLINE | ID: mdl-32522194

BACKGROUND: Rare diseases may be life-threatening or chronically debilitating conditions. Patient care needs are often complex and challenging to coordinate and deliver effectively. Rare diseases and their clinical management may therefore substantially impact on patients' health-related quality of life (HRQOL). The use of patient-reported outcome measures (PROMs) may complement clinical assessments by elucidating patients' perspectives on their health status and care priorities. This study explored the opinions of patients and clinicians on the use of PROMs in the management of patients with rare diseases in routine clinical practice. METHODS: A total of 15 semi-structured one-to-one interviews were conducted with four patients with primary sclerosing cholangitis (PSC); five renal transplant recipients; and six PSC doctors from University Hospitals Birmingham (UHB) NHS Foundation Trust. A focus group session was also conducted with 10 clinical staff members (doctors, nurses and other allied health professionals from UHB). The suitability and acceptability of the Chronic Liver Disease Questionnaire (CLDQ) and the Short Form 12 (SF12) were assessed by patients with PSC and their doctors while the Paediatric quality of life inventory Transplant Module (PedsQL-TM) and the EuroQoL-5 dimensions (EQ. 5D) were evaluated by the renal transplant recipients and their doctors. The discussions were audio recorded and transcribed verbatim. Coding of the transcripts was done using the Nvivo 11 Plus software. Thematic analysis was conducted to identify the main themes and subthemes. RESULTS: Four themes were identified, namely: (i) potential benefits of PROMs in the management of rare diseases; (ii) views on selected questionnaires; (iii) practical considerations for implementation; and (iv) potential facilitators and barriers of implementation. Patients and clinicians suggested that the use of ePROMs may facilitate patient-centred care by promoting patient-clinician communication, highlighting aspects of HRQOL that are important to patients and encouraging patient involvement in their care. They also felt that the disease-specific CLDQ and PedsQL-TM were more relevant than the generic SF12 and EQ-5D. CONCLUSIONS: Patients with rare diseases often experience impaired HRQOL. The use of an ePROM system may enhance the routine management of patients with rare diseases.


Patient Reported Outcome Measures , Quality of Life , Rare Diseases/psychology , Female , Focus Groups , Humans , Male , Qualitative Research , Rare Diseases/therapy
16.
Eur J Endocrinol ; 183(2): 141-148, 2020 Aug.
Article En | MEDLINE | ID: mdl-32413847

Objective: Given that volumes of patients and interventions are important criteria to qualify as a reference centre (RC) for the European Reference Network on Rare Endocrine Conditions (Endo-ERN), the present study aimed to evaluate the data that were reported in the original application against subsequent assessments of activity and review the criteria that may define RCs using two main thematic groups (MTGs): Pituitary and Thyroid, as examples. Methods: Review of content in application forms and continuous monitoring data and of a survey distributed to RCs. A list of 'key procedures' for the assessment of performance of RCs was composed with the help of the Pituitary and Thyroid MTG chairs. Results: In the original application, the number of undefined procedures ranged from 20 to 5500/year (Pituitary) and from 10 to 2700/year (phyroid) between applicants. In the survey, the number of key procedures per centre ranged from 18 to 150/year (Pituitary) and from 20 to 1376/year (Thyroid). The median numbers of new patients reported in the continuous monitoring program were comparable with the application and survey; however, some centres reported large variations. Conclusions: Monitoring of clinical activity in an ERN requires clear definitions that are optimally aligned with clinical practice, diagnosis registration, and hospital IT systems. This is a particular challenge in the rare disease field where the centre may also provide expert input in collaboration with local hospitals. Application of uniform definitions, in addition to condition-specific clinical benchmarks, which can include patient-reported- as well as clinician-reported outcome measures, is urgently needed to allow benchmarking of care across Endo-ERN.


Endocrine System Diseases/therapy , Rare Diseases/therapy , Data Interpretation, Statistical , Endocrine System Diseases/epidemiology , Europe/epidemiology , Humans , Outcome Assessment, Health Care , Pituitary Diseases/epidemiology , Pituitary Diseases/therapy , Rare Diseases/epidemiology , Reference Standards , Surveys and Questionnaires , Thyroid Diseases/epidemiology , Thyroid Diseases/therapy
17.
Bull Cancer ; 107(5): 601-611, 2020 May.
Article Fr | MEDLINE | ID: mdl-32305127

Sinonasal carcinomas account for 3% of ENT cancers. They are subdivided into squamous cell carcinomas (50%), adenocarcinomas [20%, mostly of intestinal type (ITAC)], and more rarely, adenoid cystic carcinomas, olfactory neuroblastomas (=esthesioneuroblastomas), neuroendocrine carcinomas or undifferentiated sinonasal carcinomas (SNUC). The 5-year survival rates are, in descending order, 72% for neuroblastomas, 63% for adenocarcinomas, 50-60% for large-cell neuroendocrine carcinomas, 53% for squamous cell carcinomas, 25-50% for adenoid cystic, 35% for small-cell neuroendocrine carcinomas and 35% for SNUC and newly discovered histologies. Surgery is the main treatment; endoscopic approaches reduce the morbidity with equivalent tumour control. Intensity-modulated radiation therapy (IMRT) is almost systematic. Nodal involvement is rare in ethmoidal adenocarcinomas and adenoid cystic carcinomas; it is intermediate and may justify prophylactic radiotherapy for N0 necks in SNUC, neuroblastoma, squamous cell carcinomas and sinonasal neuroendocrine carcinomas. IMRT or proton therapy is the mainstay of treatment of unresectable disease. Radiotherapy optimization by carbon ion therapy for adenoid cystic carcinomas, or by chemotherapy for all carcinomas with IMRT or proton therapy, is investigated within clinical trials in France. Neoadjuvant chemotherapy is reserved for rapidly progressive disease or histologies with a high metastatic potential such as neuroendocrine carcinomas or SNUC. Given their histologic and molecular specificities and different relapse patterns, an expertise of the REFCOR network, with REFCORpath review, is likely to correct diagnoses, rectify treatments, with an impact on survival.


Adenocarcinoma , Carcinoma, Squamous Cell , Paranasal Sinus Neoplasms , Rare Diseases , Adenocarcinoma/classification , Adenocarcinoma/diagnosis , Adenocarcinoma/mortality , Adenocarcinoma/therapy , Carcinoma, Adenoid Cystic/diagnosis , Carcinoma, Adenoid Cystic/mortality , Carcinoma, Adenoid Cystic/therapy , Carcinoma, Neuroendocrine/diagnosis , Carcinoma, Neuroendocrine/mortality , Carcinoma, Neuroendocrine/therapy , Carcinoma, Squamous Cell/classification , Carcinoma, Squamous Cell/diagnosis , Carcinoma, Squamous Cell/mortality , Carcinoma, Squamous Cell/therapy , Humans , Paranasal Sinus Neoplasms/classification , Paranasal Sinus Neoplasms/diagnosis , Paranasal Sinus Neoplasms/mortality , Paranasal Sinus Neoplasms/therapy , Prognosis , Rare Diseases/diagnosis , Rare Diseases/mortality , Rare Diseases/therapy
18.
Zhonghua Liu Xing Bing Xue Za Zhi ; 41(3): 400-405, 2020 Mar 10.
Article Zh | MEDLINE | ID: mdl-32294843

Objective: To understand the characteristics of 24 388 inpatients with rare diseases in Zhejiang province during 2007-2017 and provide evidence for rare disease prevention and control. Methods: Inpatient data of rare diseases and the number of hospitalization in each year were collected in 10 hospitals of class Ⅲ (A) in Zhejiang province from 2007 to 2017, and descriptive statistical analysis was used. Results: A total of 24 388 cases of rare diseases were found, accounting for 2.69‰ (24 388/9 054 201) of total hospitalized cases. The top 3 types of rare diseases were "diseases of blood and blood-forming organs and certain disorders involving immune mechanism" (32.81%, 8 001/24 388), "congenital malformations, deformations and chromosomal abnormalities" (24.87%, 6 065/24 388) and "diseases of the nervous system" (19.01%, 4 635/24 388). The number of rare disease cases increased year by year from 2007 to 2017 with an average annual growth of 19.69%, however, the proportion of rare disease cases in the annual number of hospitalized cases only showed upward trend during 2016-2017, the time distribution of different types of rare diseases had different characteristics. The male to female ratio of rare diseases cases was 1.35∶1(13 990/10 398), "diseases of the digestive system" (4.45∶1, 1 180/265), "consequences of injury, poisoning and other external causes" (3.51∶1, 281/80) and "diseases of the nervous system" (2.26∶1, 3 213/1 422) had the highest male to female ratio. The distributions of rare disease types and diseases of different types in different age groups varied. The top 10 rare diseases accounted for 53.55% (13 060/24 388) of the total cases, and the top 3 diseases were adult idiopathic neutropenia (14.41%, 3 515/24 388), corticobasal degeneration (7.60%, 1 854/24 388) and henock-schoenlein purpura (6.01%, 1 466/24 388). Conclusion: The analysis on the characteristics of 24 388 rare disease cases in Zhejiang during 2007-2017 provided reference evidence for the promotion of rare disease research, monitoring, building registration database, and development of the prevention and control strategy for rare diseases in China.


Rare Diseases/epidemiology , Rare Diseases/therapy , Adult , China/epidemiology , Databases, Factual , Female , Hospitalization/statistics & numerical data , Humans , Inpatients/statistics & numerical data , Male , Rare Diseases/prevention & control
20.
Cent Eur J Public Health ; 28(1): 82-84, 2020 Mar.
Article En | MEDLINE | ID: mdl-32228824

OBJECTIVES: About four million people are affected by rare diseases in Germany and 30 million in the EU. In 2013, a national action plan for people with rare diseases was adopted in Germany which is also aimed at improving the information situation and better gathering of information for affected patients and their families. Since then, various sources of information and medical care structures have been made available. The aim of this study was to evaluate the state of knowledge about information sources and health care centres for rare diseases among those affected. METHODS: The study was carried out as anonymous survey among the member associations of the German Alliance for Chronic Rare Diseases (German acronym ACHSE e. V.). For this, a questionnaire was developed which in addition to questions on gender, age and disease comprised free text input referring to knowledge of health care centres or expert centres and source of information on rare diseases in Germany. RESULTS: A total of 484 individuals suffering from 96 different rare diseases participated in the survey. Of these, 74.47% are aware of medical or dental care centres for treatment of their types of rare disease; 69.31% use self-help groups as a source of information, only a few respondents know government-sponsored "se-atlas" and "Orphanet". CONCLUSION: The majority of the respondents know medical care centres, most participants use self-help groups as information source, however, government-supported portals are largely unknown so that there is a need for further information in this regard.


Health Facilities , Health Knowledge, Attitudes, Practice , Information Services , Rare Diseases/therapy , Germany , Humans , Surveys and Questionnaires
...